Two Directors at Rheinmetall AG bought 227 shares at between 1,559.041EUR and 1,572.500EUR. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Gute Nachricht von Pharvaris B.V, die über vielversprechende Topline-Daten aus der pivotalen Phase III-Studie RAPIDe-3 berichtete (CN 03.12.25). Auf Basis dieser Daten plant PHVS im H1/26 die Zulassungsanträge für Deucrictibant einzureichen (bei Zulassung folgen umsatzbezogene Meilensteine). Die Aussichten für das vom Management angestrebte konzernweitem Wachstum in FY26 verbessern sich. FY 25 war ein Übergangsjahr.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.